The biorevolution podcast #31
Show notes
In some respects, 2024 has been a record year for AI in biotech, with the $1 billion founding of the antibody-centered biotech company Xaira and the awarding of the Nobel Prize in Chemistry to DeepMind researchers Demis Hassabis, John Jumper, and David Baker. However, despite years of investment and innovation, we still lack an answer to the most pressing question: Will AI revolutionize drug development, or are we in a bubble that is about to burst?
In episode 30 of the BioRevolution podcast, Andreas Horchler and Louise von Stechow explore various use cases for AI in biotech—from discovery to clinical development, from chemistry to biology, and from data-centric to algorithm-centric AI strategies—trying to assess where the biggest payoff will be.
Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.
Learn more about the future of biotech in our podcasts and keynotes. Contact us here: scientific communication: https://science-tales.com/ Podcasts: https://www.podcon.de/ Keynotes: https://www.zukunftsinstitut.de/louise-von-stechow
Image: Lucas Favre, via Unsplash. Further reading:
- OpenAI has created an AI model for longevity science | MIT Technology Review
- https://www.techlifesci.com/p/a-google-maps-of-human-cells
- https://www.cas.org/resources/cas-insights/scientific-breakthroughs-2025-emerging-trends-watch#:~:text=Scientific%20breakthroughs%3A%202025%20emerging%20trends%20to%20watch%201,7%20Quantum%20computing%20getting%20practical%20…%20Weitere%20Elemente
- Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. | Investor's Business Daily
- Regeneron CSO George Yancopoulos on AI’s hype and potential
- Science in 2025: the events to watch for in the coming year
- Artificial intelligence and obesity management: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023 - PMC
- Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs | Reuters
- Profluent Unveils OpenCRISPR-1, an AI-Designed Gene Editor
- OpenAI has created an AI model for longevity science | MIT Technology Review
- Clinical trial trends in 2025: Investments, wearables, and AI
- What will be the key trends in AI innovation in the Pharmaceutical Industry in 2025?
- Deep Genomics Introduces the Most Advanced AI Foundation Model for RNA Disease Mechanisms and Candidate Therapeutics | Deep Genomics
- U of T researchers develop new approach using quantum computers to accelerate drug discovery | Temerty Faculty of Medicine
- Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors | Nature Biotechnology
- What are AI 'world models,' and why do they matter? | TechCrunch
- Empowering biomedical discovery with AI agents: Cell
- https://youtu.be/CWEWBgVwFc8?si=dqLn2_qGflGf19xL
- Virtual lab powered by ‘AI scientists’ super-charges biomedical research
- A New Kid On the Block: AI World Models In Biotech
- 2025 AI Trends: Life Sciences Leaders on Data, Digital and AI | ZS
- Scaling gen AI in the life sciences industry | McKinsey
- https://www.geeksforgeeks.org/what-is-quantum-ai/
- Key takeaways from FDA’s draft guidance on use of AI in drug and biological life cycle | DLA Piper
- Navigating the EU AI Act: implications for regulated digital medical products | npj Digital Medicine
- Isomorphic Labs CEO Demis Hassabis bets on biotech’s AI future
- De novo designed proteins neutralize lethal snake venom toxins | Nature
- A policy framework for leveraging generative AI to address enduring challenges in clinical trials | npj Digital Medicine
- TrialGPT: NIH algorithm uses AI to match patients to clinical trials | Association of Health Care Journalists
- The promise and perils of synthetic data | TechCrunch
- Profluent | Editing the Human Genome with AI
- Nvidia Just Suffered the Biggest Single-Day Loss of Any Stock in History. Time to Buy? - 24/7 Wall St.
New comment